Outcomes of Patients with Metastatic Clear-cell Renal Cell Carcinoma Treated with Second-Line VEGFR-TKI after First-Line Immune Checkpoint Inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICI) are being increasingly utilized in the front-line (1L) setting of metastatic clear-cell renal cell carcinoma (mccRCC). Limited data exist on responses and survival on second-line (2L) VEGFR-TKI therapy after 1L ICI therapy. PATIENTS AND METHODS: This is...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Cancer
Hlavní autoři: Shah, AY, Kotecha, RR, Lemke, EA, Chandramohan, A, Chaim, JL, Msaouel, P, Xiao, L, Gao, J, Campbell, MT, Zurita, AJ, Wang, J, Corn, PG, Jonasch, E, Motzer, RJ, Sharma, P, Voss, MH, Tannir, NM
Médium: Artigo
Jazyk:Inglês
Vydáno: 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7537491/
https://ncbi.nlm.nih.gov/pubmed/31075726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2019.04.003
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky